Skip to main content

Enoxaparin Dosage

Medically reviewed by Drugs.com. Last updated on Sep 6, 2024.

Applies to the following strengths: 40 mg/0.4 mL; 60 mg/0.6 mL; 80 mg/0.8 mL; 100 mg/mL; 30 mg/0.3 mL; 300 mg/3 mL; 120 mg/0.8 mL; 150 mg/mL

Usual Adult Dose for Deep Vein Thrombosis

Outpatient: 1 mg/kg subcutaneously every 12 hours
Inpatient: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once a day at the same time every day.

Duration of therapy: At least 5 days and until a therapeutic oral anticoagulant effect has been achieved (INR 2 to 3). Average duration is 7 days; up to 17 days has been well tolerated in controlled clinical trials.

Comments: In both outpatient and inpatient treatments, warfarin sodium therapy should be initiated when appropriate (usually within 72 hours of commencing enoxaparin).

Uses:

Usual Adult Dose for Deep Vein Thrombosis - Prophylaxis

40 mg subcutaneously once a day

Duration of therapy: Usually 6 to 11 days; up to 14 days has been well tolerated in clinical trials.

Use: Prophylaxis of deep vein thrombosis (DVT) in medical patients at risk for thromboembolic complications due to severely restricted mobility during acute illness.

Usual Adult Dose for Myocardial Infarction

Unstable Angina and Non Q Wave Myocardial Infarction:
1 mg/kg subcutaneously every 12 hours in conjunction with oral aspirin therapy (100 to 325 mg once a day)

Duration of therapy: At least 2 days and until clinical stabilization. Usual duration is 2 to 8 days; up to 12.5 days has been well tolerated in clinical trials.

Use: Prophylaxis of ischemic complications of unstable angina and non Q wave myocardial infarction, when concurrently administered with aspirin.

Acute ST-Segment Elevation Myocardial Infarction (STEMI):
30 mg IV bolus once plus 1 mg/kg subcutaneously once followed by 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for the first two doses only, followed by 1 mg/kg for the remaining doses)

Duration of therapy: Optimal duration is unknown, but it is likely to be longer than 8 days.

Comments:


Use: Prophylaxis of recurrent myocardial infarction or death in patients with acute STEMI receiving thrombolysis and being managed medically or with PCI, when concurrently administered with aspirin.

Usual Adult Dose for Angina Pectoris

Unstable Angina and Non Q Wave Myocardial Infarction:
1 mg/kg subcutaneously every 12 hours in conjunction with oral aspirin therapy (100 to 325 mg once a day)

Duration of therapy: At least 2 days and until clinical stabilization. Usual duration is 2 to 8 days; up to 12.5 days has been well tolerated in clinical trials.

Use: Prophylaxis of ischemic complications of unstable angina and non Q wave myocardial infarction, when concurrently administered with aspirin.

Acute ST-Segment Elevation Myocardial Infarction (STEMI):
30 mg IV bolus once plus 1 mg/kg subcutaneously once followed by 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for the first two doses only, followed by 1 mg/kg for the remaining doses)

Duration of therapy: Optimal duration is unknown, but it is likely to be longer than 8 days.

Comments:


Use: Prophylaxis of recurrent myocardial infarction or death in patients with acute STEMI receiving thrombolysis and being managed medically or with PCI, when concurrently administered with aspirin.

Usual Adult Dose for Acute Coronary Syndrome

Unstable Angina and Non Q Wave Myocardial Infarction:
1 mg/kg subcutaneously every 12 hours in conjunction with oral aspirin therapy (100 to 325 mg once a day)

Duration of therapy: At least 2 days and until clinical stabilization. Usual duration is 2 to 8 days; up to 12.5 days has been well tolerated in clinical trials.

Use: Prophylaxis of ischemic complications of unstable angina and non Q wave myocardial infarction, when concurrently administered with aspirin.

Acute ST-Segment Elevation Myocardial Infarction (STEMI):
30 mg IV bolus once plus 1 mg/kg subcutaneously once followed by 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for the first two doses only, followed by 1 mg/kg for the remaining doses)

Duration of therapy: Optimal duration is unknown, but it is likely to be longer than 8 days.

Comments:


Use: Prophylaxis of recurrent myocardial infarction or death in patients with acute STEMI receiving thrombolysis and being managed medically or with PCI, when concurrently administered with aspirin.

Usual Adult Dose for Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery

30 mg subcutaneously every 12 hours. Provided that hemostasis has been established, the initial dose should be given 12 to 24 hours after surgery. For hip replacement surgery, a dose of 40 mg subcutaneously once a day given initially 12 hours prior to surgery may be considered. Following the initial phase of thromboprophylaxis in hip replacement surgery patients, continued prophylaxis with 40 mg subcutaneously once a day for 3 weeks is recommended.

Duration of therapy: Usually 7 to 10 days; up to 14 days has been well tolerated in clinical trials.

Uses:

Usual Adult Dose for Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery

30 mg subcutaneously every 12 hours. Provided that hemostasis has been established, the initial dose should be given 12 to 24 hours after surgery. For hip replacement surgery, a dose of 40 mg subcutaneously once a day given initially 12 hours prior to surgery may be considered. Following the initial phase of thromboprophylaxis in hip replacement surgery patients, continued prophylaxis with 40 mg subcutaneously once a day for 3 weeks is recommended.

Duration of therapy: Usually 7 to 10 days; up to 14 days has been well tolerated in clinical trials.

Uses:

Usual Adult Dose for Deep Vein Thrombosis Prophylaxis after Abdominal Surgery

40 mg subcutaneously once a day with the initial dose given 2 hours prior to surgery

Duration of therapy: Usually 7 to 10 days; up to 12 days has been well tolerated in clinical trials.

Use: Prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery who are at risk for thromboembolic complications.

Usual Geriatric Dose for Myocardial Infarction

75 Years or Older:
Initial dose: 0.75 mg/kg subcutaneously every 12 hours (maximum 75 mg for first two doses only, followed by 0.75 mg/kg for the remaining doses).

Comments:


Use: Treatment of acute ST-segment elevation myocardial infarction.

Usual Pediatric Dose for Deep Vein Thrombosis

American College of Chest Physicians (ACCP) recommends the following:
Less than 2 months: 1.5 mg/kg subcutaneously every 12 hours
2 months to 17 years: 1 mg/kg subcutaneously every 12 hours

Usual Pediatric Dose for Deep Vein Thrombosis - Prophylaxis

American College of Chest Physicians (ACCP) recommends the following:
Less than 2 months: 0.75 mg/kg subcutaneously every 12 hours
2 months to 17 years: 0.5 mg/kg subcutaneously every 12 hours

Renal Dose Adjustments

Mild to moderate renal dysfunction (CrCl 30 to 80 mL/min): Use with caution
Severe renal dysfunction (CrCl less than 30 mL/min):

Liver Dose Adjustments

Use with caution

Precautions

US BOXED WARNING:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice: The manufacturer product information should be consulted.

Storage requirements: Do not store multiple-use vials for more than 28 days after the first use.

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

IV compatibility:


General: This drug is characterized by a higher ratio of antithrombotic (anti-Factor Xa) activity to anticoagulant (anti-Factor IIa) activity compared to heparin.

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.